| Primary |
| Type 2 Diabetes Mellitus |
65.6% |
| Product Used For Unknown Indication |
29.4% |
| Diabetes Mellitus |
3.7% |
| Glucose Tolerance Impaired |
0.5% |
| Type 1 Diabetes Mellitus |
0.3% |
| Weight Decreased |
0.2% |
| Blood Glucose Increased |
0.1% |
| Metabolic Syndrome |
0.1% |
| Polycystic Ovaries |
0.1% |
| Rheumatoid Arthritis |
0.1% |
| Weight Increased |
0.1% |
|
| Nausea |
23.0% |
| Pancreatitis |
14.6% |
| Vomiting |
11.9% |
| Blood Glucose Increased |
8.7% |
| Weight Decreased |
5.5% |
| Injection Site Pain |
5.0% |
| Decreased Appetite |
3.7% |
| Diarrhoea |
3.6% |
| Injection Site Haematoma |
3.3% |
| Injection Site Urticaria |
2.3% |
| Blood Glucose Decreased |
2.2% |
| Headache |
2.2% |
| Drug Ineffective |
2.1% |
| Malaise |
2.1% |
| Pancreatitis Acute |
2.0% |
| Constipation |
1.7% |
| Weight Increased |
1.6% |
| Injection Site Mass |
1.5% |
| Urticaria |
1.5% |
| Fatigue |
1.4% |
|
| Secondary |
| Type 2 Diabetes Mellitus |
56.1% |
| Product Used For Unknown Indication |
31.7% |
| Diabetes Mellitus |
12.2% |
|
| Blood Glucose Increased |
25.0% |
| Malaise |
10.0% |
| Blood Pressure Increased |
5.0% |
| Decreased Appetite |
5.0% |
| Diabetes Mellitus Inadequate Control |
5.0% |
| Flatulence |
5.0% |
| Injection Site Pain |
5.0% |
| Injection Site Rash |
5.0% |
| Injection Site Urticaria |
5.0% |
| Myalgia |
5.0% |
| Nausea |
5.0% |
| Needle Issue |
5.0% |
| Vomiting |
5.0% |
| Weight Increased |
5.0% |
| Wrong Drug Administered |
5.0% |
|
| Concomitant |
| Type 2 Diabetes Mellitus |
100.0% |
|
| Weight Fluctuation |
100.0% |
|
